Abbott Laboratories (ABT) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.054x

Based on the latest financial reports, Abbott Laboratories (ABT) has a cash flow conversion efficiency ratio of 0.054x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($2.79 Billion) by net assets ($51.26 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ABT cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

Abbott Laboratories - Cash Flow Conversion Efficiency Trend (1989–2024)

This chart illustrates how Abbott Laboratories's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Abbott Laboratories Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Abbott Laboratories ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Deutsche Telekom AG
XETRA:DTE
0.117x
Deere & Company
NYSE:DE
-0.034x
Charles Schwab Corp
NYSE:SCHW
0.177x
BlackRock Inc
NYSE:BLK
-0.017x
Gilead Sciences Inc
NASDAQ:GILD
0.147x
Southern Copper Corporation
NYSE:SCCO
0.143x
AT&T Inc.
NYSE:T
0.059x
Union Pacific Corporation
NYSE:UNP
0.126x

Annual Cash Flow Conversion Efficiency for Abbott Laboratories (1989–2024)

The table below shows the annual cash flow conversion efficiency of Abbott Laboratories from 1989 to 2024. For the full company profile with market capitalisation and key ratios, see Abbott Laboratories (ABT) market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 $47.90 Billion $8.56 Billion 0.179x -4.46%
2023-12-31 $38.83 Billion $7.26 Billion 0.187x -27.97%
2022-12-31 $36.91 Billion $9.58 Billion 0.260x -11.21%
2021-12-31 $36.02 Billion $10.53 Billion 0.292x +22.13%
2020-12-31 $33.00 Billion $7.90 Billion 0.239x +22.12%
2019-12-31 $31.30 Billion $6.14 Billion 0.196x -4.40%
2018-12-31 $30.72 Billion $6.30 Billion 0.205x +14.49%
2017-12-31 $31.10 Billion $5.57 Billion 0.179x +28.96%
2016-12-31 $23.06 Billion $3.20 Billion 0.139x +12.76%
2015-12-31 $24.08 Billion $2.97 Billion 0.123x -19.04%
2014-12-31 $24.16 Billion $3.67 Billion 0.152x +15.65%
2013-12-31 $25.27 Billion $3.32 Billion 0.132x -62.13%
2012-12-31 $26.81 Billion $9.31 Billion 0.347x -5.02%
2011-12-31 $24.53 Billion $8.97 Billion 0.366x -1.25%
2010-12-31 $23.59 Billion $8.74 Billion 0.370x +17.41%
2009-12-31 $23.06 Billion $7.28 Billion 0.315x -24.92%
2008-12-31 $17.48 Billion $7.34 Billion 0.420x +44.10%
2007-12-31 $17.78 Billion $5.18 Billion 0.292x -23.11%
2006-12-31 $14.05 Billion $5.33 Billion 0.379x +5.64%
2005-12-31 $14.42 Billion $5.17 Billion 0.359x +16.66%
2004-12-31 $14.33 Billion $4.41 Billion 0.308x +7.36%
2003-12-31 $13.07 Billion $3.75 Billion 0.287x -26.93%
2002-12-31 $10.66 Billion $4.18 Billion 0.392x -0.38%
2001-12-31 $9.06 Billion $3.57 Billion 0.394x +8.87%
2000-12-31 $8.57 Billion $3.10 Billion 0.362x -8.56%
1999-12-31 $7.43 Billion $2.94 Billion 0.395x -17.32%
1998-12-31 $5.71 Billion $2.73 Billion 0.478x -9.05%
1997-12-31 $5.00 Billion $2.63 Billion 0.526x +6.42%
1996-12-31 $4.82 Billion $2.38 Billion 0.494x +10.55%
1995-12-31 $4.40 Billion $1.97 Billion 0.447x -18.17%
1994-12-31 $4.05 Billion $2.21 Billion 0.546x +8.70%
1993-12-31 $3.67 Billion $1.85 Billion 0.503x +21.14%
1992-12-31 $3.35 Billion $1.39 Billion 0.415x -8.56%
1991-12-31 $3.20 Billion $1.45 Billion 0.454x +7.05%
1990-12-31 $2.83 Billion $1.20 Billion 0.424x +20.37%
1989-12-31 $2.73 Billion $959.90 Million 0.352x --

About Abbott Laboratories

NYSE:ABT USA Medical Devices
Market Cap
$153.73 Billion
Market Cap Rank
#147 Global
#82 in USA
Share Price
$88.41
Change (1 day)
-0.10%
52-Week Range
$82.56 - $138.08
All Time High
$140.22
About

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary s… Read more